Biogen Disappointed by INESSS Recommendation on SKYCLARYS™ and its Impact on Quebec Patients with Friedreich Ataxia Français
TORONTO, June 5, 2025 /CNW/ - Biogen Canada Inc. is disappointed by INESSS's recommendation against listing SKYCLARYS™ (omaveloxolone), despite its therapeutic potential for individuals living with Friedreich ataxia (FA) — a community in urgent need of treatment options.
A decision to not reimburse SKYCLARYS would leave individuals living with FA in Quebec without public access to the only approved treatment for this rare, progressive, and life-shortening neurodegenerative disease – despite a clear and ongoing medical need. 1 As the only approved treatment targeting disease progression, SKYCLARYS addresses a long-standing gap in care for Canadians living with FA, particularly in Quebec where a notable concentration of cases highlights the importance of equitable access. 2
"After years of research and failed trials with no approved treatments until now, the availability of a therapy with a demonstrated ability to slow disease progression and preserve mobility is profoundly meaningful for the Friedreich ataxia community, offering renewed hope and the possibility of managing the disease and care in FA. We remain committed to working with INESSS, government authorities, and clinicians to help ensure access to SKYCLARYS for eligible FA patients in Quebec and the rest of Canada," said Eric Tse, General Manager, Biogen Canada.
SKYCLARYS was approved in March 2025 under Health Canada's Priority Review process as the first and only treatment in Canada to target the underlying mechanisms of FA in patients aged 16 and older. Canada's Drug Agency (CDA-AMC), which advises on drug reimbursement across Canada's public drug programs outside of Quebec, has issued a positive draft recommendation recognizing SKYCLARYS as an important therapeutic option, valued by patients, caregivers, and clinicians for its potential to improve quality of life and preserve function. 3
About SKYCLARYS™ (omaveloxolone)
SKYCLARYS™ (omaveloxolone) is an oral, once-daily medication indicated for the treatment of Friedreich ataxia (FA) in adults and adolescents aged 16 years and older in the United States (U.S.), European Union and Canada. 4,5,6 SKYCLARYS received Orphan Drug, Fast Track, and Rare Pediatric Disease designations from the U.S. Food and Drug Administration (FDA). 5 The European Commission granted Orphan Drug designation in Europe to SKYCLARYS for the treatment of FA. 6 In Canada, marketing authorization for SKYCLARYS was granted under the Health Canada Priority Review process. 7
Biogen continues to be dedicated to advancing research and development efforts to enhance the understanding of FA and improve patient outcomes. This includes an ongoing, open-label, Phase 1 study to evaluate the use of SKYCLARYS in in pediatric patients aged 2 to 15 years. More details can be found at clinicaltrials.gov.
About Biogen
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment, to deliver long-term growth.
Biogen has been proudly serving Canadian patients for more than 25 years. For information about Biogen Canada, please visit www.biogen.ca.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Toronto Star
6 hours ago
- Toronto Star
Teva birth control pills recalled across Canada over extra placebos
Birth control medication is being pulled from Canadian shelves over extra placebo tablets, Health Canada says. The recall concerns Teva Canada's Seasonale tablet with lot numbers 100059661 and 100069150, according to the agency's recall notice. Health Canada is urging patients not to skip doses or stop taking their birth control. But if your package contains white placebo pills in the first or second blister card tray, don't take them, and return the pills to your pharmacy for a replacement. ARTICLE CONTINUES BELOW If you can't get to a pharmacy right away, take the next pink active pill in the proper order, as laid out in the instructions, until you can get a replacement. If you took a white placebo pill instead of an active pink pill from one of the first two trays, or if you are unsure, you should also use another method of non-hormonal contraception and consult with your health care professional.
Cision Canada
8 hours ago
- Cision Canada
Public Advisory - Health Canada warns consumers not to inhale nitrous oxide, also known as laughing gas, recreationally Français
Product: Various nitrous oxide products Issue: Health products – Product safety; Unauthorized product What to do: Do not inhale nitrous oxide products for recreational purposes. If you use prescription nitrous oxide recreationally and experience side effects, seek medical attention immediately. Affected products Various nitrous oxide products. Examples of seized products include: Bamboozle Need Whip Primewhip Primewhip XL Space Gas Issue Health Canada is warning consumers about the serious health risks, including death, of inhaling nitrous oxide products, also known as laughing gas and by various street names, such as "whippets," "hippy crack," "NOS" and "nang," for recreational purposes. In Canada, nitrous oxide sold for inhalation is a drug and can only be administered by an authorized health care professional for legitimate and safe uses, such as in medical and dental procedures for sedation and pain relief. It is also in cream dispensers and other food tools where it is not meant to be inhaled. When inhaled—or "huffed" —nitrous oxide can cause euphoria and relaxation. It can also cause serious adverse effects such as: loss of consciousness and in some cases, death birth defects anemia, vitamin B12 deficiency impaired bowel and bladder function confusion, agitation, delusions, hallucinations, paranoia and depression increased heart rate, palpitations, low blood pressure, heart attack and stroke lack of oxygen in the body (asphyxia), blood clots in the extremities and in the lungs, and air leaks into the space between the lung and chest wall (pneumothorax) tingling, numbness and weakness of the limbs and extremities (fingers and toes), uncoordinated walking and falls nerve damage, spinal cord degeneration, prolonged pain and, in severe cases, permanent paralysis Repeated use increases the likelihood of severe outcomes and may result in lasting neurological damage, even after stopping use. Regular use can also lead to addiction and withdrawal symptoms. Advertising and selling nitrous oxide products for inhalation to the public is strictly prohibited. However, Health Canada is aware that these products are being sold online and in retail stores. These products may be deceptively labelled: as "whip cream chargers," in flavours, which are not permitted, in stores you would not expect to find whipped cream chargers; and in large containers you would not expect for dispensing whipped cream. Health Canada has not reviewed these products, which are regulated as drugs, for safety, efficacy or quality. Also, they could be contaminated in ways that create additional health risks when inhaled. Health Canada strongly advises that consumers not inhale any nitrous oxide products for recreational purposes. Health Canada has seized several unauthorized nitrous oxide products and has worked with Canada Border Services Agency (CBSA) to stop unauthorized shipments from entering the country. The Department will continue to take action to stop the sale of unauthorized products and to work with CBSA to help prevent further importations. What you should do
Cision Canada
9 hours ago
- Cision Canada
Public Advisory - One lot of Seasonique birth control recalled due to possible extra yellow pills (ethinyl estradiol only) Français
Product: Seasonique (DIN 02346176) Issue: Health products - Product quality What to do: Do not skip doses or stop taking Seasonique. If your package contains an extra row of yellow pills in Tray 1 and/or 2 of the blister cards, do not take them. Instead, return the product to your pharmacy for a replacement or alternative product. If you cannot get to a pharmacy right away, take the next blue-green pill in the proper order as noted in the instructions until you are able to contact your pharmacist and obtain a replacement or alternative product. Affected products: Issue Teva Canada Ltd. is recalling one lot of Seasonique prescription birth control due to the possibility of having an extra row of yellow pills in tray 1 and/or 2 of the blister cards, where there should be none. This may increase the risk of pregnancy. When packaged correctly, as shown in the picture, Seasonique pills come in extended-cycle tablet dispensers, each containing a 13-week (91-day) supply of pills divided in three blister cards: Tray 1 and Tray 2 each contain a blister card with 28 blue-green tablets (levonorgestrel and ethinyl estradiol) Tray 3 contains a blister card with 35 tablets: 28 blue-green tablets (levonorgestrel and ethinyl estradiol) and 7 yellow tablets (ethinyl estradiol) Users can expect to have four periods a year, with bleeding occurring while taking the yellow pills. Seasonique should be taken daily unless otherwise directed by your prescriber. Taking the pills in the proper order, according to the product instructions, is important for preventing pregnancy. Taking the wrong pill or a pill out of order could lead to an unplanned pregnancy or other side effects, including spotting and irregular bleeding. Health Canada is monitoring the company's recall and investigation, including its implementation of corrective and preventative actions. The Department will inform the public if any new health risks are identified. What you should do: Do not stop taking Seasonique. Do not skip taking any blue–green pills. Check your package. If your package contains an extra row of yellow pills in Tray 1 and/or 2 of the blister cards, do not take them. Instead, return it to your pharmacy for a replacement or an alternative product. If you cannot get to a pharmacy right away, take the next blue–green pill in the proper order as noted in the instructions until you are able to contact your pharmacist and obtain a replacement or alternative product. If you are unsure whether your package contains the correct pills, talk to your pharmacist. If you took a yellow pill instead of a blue-green pill from Tray 1 and/or 2, or if you are unsure, you should also use another method of non-hormonal back-up contraception (such as condoms) and consult with your health care professional. Talk to a health care professional if you have any other questions or concerns about your birth control product. Contact Teva Canada Ltd. by calling toll-free at 1-800-268-4127, Option 3, or by email at [email protected] if you have questions about this recall. Report any health product-related adverse reactions or complaints to Health Canada
